Stay updated on Amgen Press Releases
Sign up to get notified when there's something new on the Amgen Press Releases page.

Latest updates to the Amgen Press Releases page
- CheckyesterdayChange DetectedThree new press releases were added: AMGEN ANNOUNCES WEBCAST OF 2025 THIRD QUARTER FINANCIAL RESULTS; AMGEN'S LANDMARK PHASE 3 REPATHA DATA TO BE PRESENTED AS LATE BREAKER AT THE AMERICAN HEART ASSOCIATION SCIENTIFIC SESSIONS 2025; AMGEN ANNOUNCES 2025 FOURTH QUARTER DIVIDEND.SummaryDifference9%

- Check8 days agoNo Change Detected
- Check15 days agoChange DetectedAdded three new major items: Amgen financial results webcast, FDA approval of Lumakras in combination with Vectibix for chemo-refractory KRAS G12C metastatic colorectal cancer, and Amgen’s presentation at the 43rd annual J.P. Morgan Healthcare Conference.SummaryDifference100%

- Check22 days agoChange Detected- Removed three dated items: a 2025 financial results webcast, a 2025 drug approval press release, and a 2025 conference presentation notice. This trims time-sensitive, high-importance content without introducing new information.SummaryDifference100%

- Check30 days agoChange DetectedRemoved three time-sensitive, high-importance items (financial results webcast, FDA approval news, and conference presentation) related to Amgen; overall decrease in core, high-priority content.SummaryDifference100%

- Check44 days agoChange DetectedAdded three new Amgen updates: Q4/QY financial results webcast, FDA approval of Lumakras in combination with Vecitrib for a specific colorectal cancer, and a presentation at the JP Morgan healthcare conference.SummaryDifference100%

- Check66 days agoChange DetectedThe webpage has removed several important announcements related to Amgen's financial results and FDA approvals, which could impact stakeholders and investors.SummaryDifference100%

Stay in the know with updates to Amgen Press Releases
Enter your email address, and we'll notify you when there's something new on the Amgen Press Releases page.